← Library
A cosmetic ingredient, not regulated or approved as a drug. This page is educational information only, not medical advice.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Palmitoyl tetrapeptide-7

Cosmetic ingredient

Cosmetic signal peptide

Also known as: Pal-GQPR, Rigin, N-Palmitoylrigin, Palmitoyl-GQPR, Pal-Gly-Gln-Pro-Arg-OH, Palmitoyl Tetrapeptide-3, PALMITOYL TETRAPEPTIDE 3, Palmitoyl tetrapeptide 7

Evidence score
48/ 100
Emerging evidence

Early evidence, mostly unproven in humans

  • Regulatory standing. Cosmetic ingredient, not regulated as a drug
  • Limited human data. Some human data exists, not conclusive
  • Registered human trials. 1 registered study on ClinicalTrials.gov, most advanced Phase 4
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Palmitoyl tetrapeptide-7, also sold as Rigin or Pal-GQPR, is a short synthetic peptide (glycine, glutamine, proline, arginine) attached to a palmitic acid fatty chain to help it penetrate skin. It is used as an ingredient in anti-aging skin care and is thought to reduce signaling by interleukin-6, an inflammatory messenger, in skin cells.

What the evidence shows

Automatic summaryLimited human data

It is regulated as a cosmetic ingredient, not an FDA-approved drug, and most support for its effects comes from lab studies and manufacturer-sponsored cosmetic testing. Only one registered human trial and a small body of published papers exist, so independent human evidence for meaningful skin benefits remains thin.

Key facts

Molecular formula
C34H62N8O7
Molecular weight
694.9 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

1registered studies
Phase 4most advanced phase
1completed (sample)
0recruiting (sample)

Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

Phase 4CompletedNCT05932732

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

12papers referencing Palmitoyl tetrapeptide-7

Usage of Synthetic Peptides in Cosmetics for Sensitive Skin.

Pharmaceuticals (Basel)2021

Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications.

J Cosmet Dermatol2015

Injectable polypeptide/chitosan hydrogel with loaded stem cells and rapid gelation promoting angiogenesis for diabetic wound healing.

Int J Biol Macromol2025

Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.

Skin Res Technol2024

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.